Identification of markers of possible prognostic value in 57 giant cell tumors of bone

Oncology Reports

Volumn 10, Issue 2, 2003, Pages 351-356

  Gamberi, Gabriella ^a   Serra, Massimo ^a   Ragazzini, Paola ^a   Magagnoli, Giovanna ^a   Pazzaglia, Laura ^a   Ponticelli, Francesca ^a   Ferrari, Cristina ^a   Zanasi, Manuela ^a   Bertoni, Franco ^a   Picci, Piero ^a   Benassi, M Serena ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

Giant cell tumor; Interleukin 6; Proteases

Indexed keywords

CELL SURFACE RECEPTOR; INTERLEUKIN 6; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR, UROKINASE RECEPTORS; TUMOR MARKER; TUMOR PROTEIN; UROKINASE;

ADULT; ARTICLE; BONE TUMOR; DRUG ANTAGONISM; ENZYME IMMUNOASSAY; FEMALE; HUMAN; LUNG TUMOR; MALE; METABOLISM; METASTASIS; OSTEOCLASTOMA; PATHOLOGY; PROGNOSIS; UPREGULATION;

ADULT; BONE NEOPLASMS; FEMALE; GIANT CELL TUMOR OF BONE; HUMANS; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-6; LUNG NEOPLASMS; MALE; NEOPLASM PROTEINS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; RECEPTORS, CELL SURFACE; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; URINARY PLASMINOGEN ACTIVATOR;

EID: 18544399193     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.10.2.351     Document Type: Article

References (37)

1. Campanacci M: Bone and Soft Tissue Tumors. Springer-Verlag, Wien, New York, 1999.
2. Bertoni F, Present D and Enneking WF: Giant-cell tumor of bone with pulmonary metastases. J Bone Joint Surg Am 67: 890-900, 1985. (Pubitemid 15240314)
3. Goldring G, Roelke M, Petrison K and Bhan A: Human giant cell tumor of bone: identification and characterisation of cell types. J Clin Invest 79: 483-491, 1987. (Pubitemid 17009684)
4. Katz E, Nyska M, Okon E, Zajiak G and Robin G: Growth rate analysis of lung metastases from histologically benign giant cell tumours of bone. Cancer 59: 1831-1836, 1987. (Pubitemid 17075433)
5. Ladanyi M, Tragano F and Huvos A: Benign metastasizing giant cell tumours of bone. Cancer 64: 1521-1526, 1989.
6. Campanacci M, Bagnara G, Serra M, Giovannini M, Tomasi P, Piled S, Poggi S, Lollini PL, Picci P and Paolucci G: Giant cell tumor of bone: a model for the in vitro human osteoclast characterization. Tumori 75: 389-395, 1989. (Pubitemid 19260357)
7. Campanacci M: Bone and Soft Tissue Tumors. Springer-Verlag, Wien, 1990.
8. Komiya S, Sasaguri Y, Inoue A, Kakashima M, Yamamoto S, Yanagida I and Morimatsu M: Characterization of cells cultured from human giant-cell tumors of bone. Clin Orthop 258: 304-309, 1990.
9. Ohsaki Y, Takahashi S, Scarcez T, Demulder A, Nishihara T, Williams R and Roodman GD: Evidence for an autocrine/ paracrine role for interleukin-6 in bone resoption by giant cell tumor of bone. Endocrinology 131: 2229-2234, 1992.
10. Grano M, Colucci S, Portuguese A, De Lellis M, Zambonin G, Teti A and Zambonin Zallone A: New model for bone resorption study in vitro: human osteoclast-like cells from giant cell tumors of bone. J Bone Miner Res 7: 1013-1020, 1994. (Pubitemid 24191788)
11. Giovannini M, Strippoli P, Serra M, Sironi M, Fincato G, Colotta F, Bonafé M, Biunno I, Mantovani A, Zecchi Orlandini S, Brandi ML, Pastano R and Bagnara GP: Production of interleukin-6 by human osteoclast-like cells from giant cell tumor of bone. Int J Oncol 8: 297-303, 1996. (Pubitemid 26047258)
12. Pollanen J, Saksela O, Salonen E, Andreasen P, Nieksen L, Dano K and Vaheri A: Distinct localisations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells. J Cell Biol 104: 1085-1096, 1987. (Pubitemid 17068679)
13. Kwaan H: The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev 11: 291-311, 1992.
14. Andreasen PA, Sottrup-Jensen L, Kjoller L, Nykaer A, Moestrup SK, Petersen CM and Gliemann F: Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes. FEBS Lett 338: 239-245, 1994. (Pubitemid 24056729)
15. Andreasen P, Kjoller L, Christensen L and Duffy M: The urochinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22, 1997. (Pubitemid 27314632)
16. Borgfeldt C, Casslen B, Liu C, Hansson S, Lecander I and Astedt B: High tissue content of urokinase plasminogen activator (uPA) is associated with high stromal expression of uPA mRNA in poorly differentiated serous ovarian carcinoma. Int J Cancer 79: 588-595, 1998. (Pubitemid 28549469)
17. Duggan C, Maguire T, McDermott E, O'Higgins N, Fenelly J and Duffy M: Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer 61: 597-600, 1995.
18. Oka T, Ishida T, Nishino T and Sugimachi K: Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma. Cancer Res 51: 3522-3525, 1991.
19. Hasui Y, Marutsuka K, Suzumiya J, Kitada S, Osada J and Sumiyoshi A: The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer. Int J Cancer 50: 871-873, 1992.
20. Nekarda H, Siewert J, Schmitt M and Ulm K: Tumor-associated proteolytic factors uPA and PAI1 and survival in totally resected gastric cancer. Lancet 343: 117, 1994. (Pubitemid 24019365)
21. Mulcahy H, Duffy M, Gibbons D, McCarthy P, Parfrey NA, O'Donoghue DP and Sheahan K: Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet 344: 583-584, 1994. (Pubitemid 24267218)
22. Bindal A, Hammoud M, Shi W, Wu S, Sawaya R and Rao J: Prognostic significance of proteolytic enzymes in human brain tumors. J Neurooncol 22: 101-110, 1994.
23. Athanasou N, Bliss E, Gatter K, Heryet A, Woods C and McGee J: An immunohistological study of giant cell tumor of bone: evidence for an osteoclast origin of the giant cells. J Pathol 147: 153-158, 1985. (Pubitemid 16231731)
24. Campanacci M, Baldwin N, Bozioni S and Sudanese A: Giant cell tumor of bone. J Bone Joint Surg Am 69: 106-114, 1987.
25. Roodman G: Role of cytokines in the regulation of bone resorption. Calcif Tissue Int 53: 94-98, 1993.
26. Pedersen H, Brunner N, Francis D, Osterlind K, Rönne E, Hansen HH, Dano K and Grondahl-Hansen J: Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 54: 4671-4675, 1994. (Pubitemid 24276492)
27. Ishimi Y, Miyaura C, Jin C, Akatsu T, Abe E, Nakamura Y, Yamaguchi A, Yoshiki S, Matsuda T, Hirano T, Kishimoto T and Suda T: IL-6 is produced by osteoblasts and induces bone resorption. J Immunol145: 3297-3303, 1990.
28. Roodman G: Interleukin-6: an osteotropic factor? J Bone Miner Res 7: 475-478, 1992.
29. Littlewood A, Russel J, Harvey G, Hughes D, Rüssel R and Gowen M: The modulation of exspression of IL-6 and its receptor in human osteoblasts in vitro. Endocrinology 129: 1513-1520, 1991.
30. Dano K, Andreasen P, Grondahl-Hansen J, Kristensen P, Nielsen S and Skriver L: Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 44: 139-266, 1985.
31. Foekens J, Look M, Peters H, van Putten W, Portengen H and Klijn J: Urokinase-type plasminogen activator and its inhibitor PAI1: predictors of poor responce to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 87: 751-756, 1995.
32. Foekens J, Schmitt M, van Putten W, Peters HA, Kramer MD, Janicke F and Klijn JG: Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12: 1648-1658, 1994. (Pubitemid 24245001)
33. Janicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hofler H and Graeff H: Urokinase (uPA) and its inhibitor PAI1 are strong and indipendent prognostic factors in node negative breast cancer. Breast Cancer Res Treat 24: 195-208, 1993. (Pubitemid 23062819)
34. Grondahl-Hansen J, Ralfkiaer ELK, Kristensen P, Lund L and Dano K: Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am J Pathol 138: 111-117, 1991.
35. Pyke C, Kristesen P, Ralfkiaer E, Grondahl-Hansen J, Eriksen J, Blasi F and Dano K: Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinoma. Am J Pathol 38: 1059-1067, 1991.
36. Duffy MJ: Proteases as prognostic markers in cancer. Clin Cancer Res 2: 613-618, 1996.
37. De Vries T, Quax P, Denijn M, Verrijp KN, Verheijen JH, Verspaget HW, Weidie UK, Ruiter DJ and van Muijen GNP: Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol 144:70-81, 1994. (Pubitemid 24158361)